Evidence map›Paper›PMID 34894134›Full record

ArticleThe Journal of infectious diseases2022

A Gonococcal Vaccine Has the Potential to Rapidly Reduce the Incidence of Neisseria gonorrhoeae Infection Among Urban Men Who Have Sex With Men.

Ben B Hui, Thilini N Padeniya, Nic Rebuli, Richard T Gray, James G Wood, Basil Donovan, Qibin Duan, Rebecca Guy, Jane S Hocking, Monica M Lahra and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Comparing Strategies to Introduce Two New Antibiotics for Gonorrhea: A Modeling Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Clinical microbiology reviews · 2024
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Immune responses toFrontiers in immunology · 2023
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Ben B HuiThe Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-6567-5821
Thilini N PadeniyaThe Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Nic RebuliThe Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Richard T GrayThe Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
James G WoodSchool of Population Health, University of New South Wales, Sydney, New South Wales, Australia.
Basil DonovanThe Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Qibin DuanThe Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Rebecca GuyThe Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Jane S HockingMelbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
Monica M LahraMicrobiology Department, New South Wales Health Pathology, The Prince of Wales Hospital, Randwick, New South Wales, Australia.
David A LewisWestern Sydney Sexual Health Centre, Western Sydney Local Health District, Parramatta, New South Wales, Australia.
David M WhileyCentre for Clinical Research, University of Queensland, Brisbane, Queensland, Australia.
David G ReganThe Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Kate L SeibInstitute for Glycomics, Griffith University, Gold Coast, Queensland, Australia.
UNSW Sydney · AUGriffith University · AUQueensland University of Technology · AUThe University of Melbourne · AUThe University of Queensland · AUThe University of Sydney · AU

Funding

Using gonococcal TonB-dependent transporters as vaccine antigensU19AI144182 · NIAID · GEORGIA STATE UNIVERSITY · PI SEIB, KATE LOUISE · 2019 to 2023
$9.3M
NIAID NIH HHS U19 AI144182
6 · The paper itself

Abstract

backgroundA gonococcal vaccine is urgently needed due to increasing gonorrhea incidence and emerging multidrug-resistant gonococcal strains worldwide. Men who have sex with men (MSM) have among the highest incidences of gonorrhea and may be a key target population for vaccination when available.

methodsAn individual-based, anatomical site-specific mathematical model was used to simulate Neisseria gonorrhoeae transmission in a population of 10 000 MSM. The impact of vaccination on gonorrhea prevalence was assessed.

resultsWith a gonococcal vaccine of 100% or 50% protective efficacy, gonorrhea prevalence could be reduced by 94% or 62%, respectively, within 2 years if 30% of MSM are vaccinated on presentation for sexually transmitted infection (STI) testing. Elimination of gonorrhea is possible within 8 years with vaccines of ≥ 50% efficacy lasting 2 years, providing a booster vaccination is available every 3 years on average. A vaccine's impact may be reduced if it is not effective at all anatomical sites.

conclusionsOur study indicates that with a vaccine of modest efficacy and an immunization strategy that targets MSM presenting for STI screening, the prevalence of gonorrhea in this population could be rapidly and substantially reduced.

Indexed as

GonorrheaSexual and Gender MinoritiesBacterial VaccinesHomosexuality, MaleHumansIncidenceMaleNeisseria gonorrhoeaeBacterial Vaccinesgonococcal vaccinegonorrheaindividual-based modelmathematical modelmen who have sex with men (MSM)Neisseria gonorrhoeaesexually transmitted infection

Identifiers

PMID34894134
PMCPMC8922007
OpenAlexW4200425716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.